Background
==========

It is widely accepted that *Helicobacter pylori*, a Gram negative microaerophylic bacterium, is involved in several clinical digestive tract conditions such as chronic gastritis, peptic and duodenal ulcers, gastric cancer and lymphoproliferative disorders \[[@B1]\]. Treatment of *H. pylori* infection results in ulcer healing and in a reduction of the risk of gastric cancer and lymphoma \[[@B2],[@B3]\].

Once the bacterium *H. pylori* is detected in altered gastric mucosa, the indicated treatment consists of a triple antibiotic regimen including methronidazol, clarithromycin, amoxicillin, tinidazole, tetracycline and fluoroquinolones associated with a pump proton inhibitor such as omeprazol, lansoprazol or pantoprazol \[[@B4]-[@B6]\]. *H. pylori* eradication rates with a number of combined agents and regimens are close to 80% \[[@B7]-[@B9]\], varying from country to country and regionally, within countries \[[@B10]\]. Several factors contribute to this low rate of *H. pylori* healing including the inefficiency of the antibiotic penetration in the gastric mucosa, inactivation of the antibiotic by the acid secretion of the stomach \[[@B11]\], lack of the patient compliance \[[@B12]\] and principally, emergency cases and increasing *H. pylori* antibiotic resistant strains \[[@B13]\]. Thus, regional *H. pylori* resistance surveillance is of great importance for test and treatment strategies.

In Brazil, a country of continental dimensions, the majority of practicing clinicians employ the classical triple regimen composed of clarithromycin, amoxicillin and a proton pump inhibitor for seven days as first line therapy to overcome *H. pylori* infection \[[@B5],[@B14]\]. This regimen has been proved to become inefficient worldwide, mainly as a result of the emergence and increase of *H. pylori* strains resistant to clarithromycin, which reduces the bacterium treatment efficiency from 55% to 100% \[[@B15]-[@B18]\]. Among Brazilian localities, *H. pylori* clarithromycin resistance presents high prevalence, varying from 7-16% in adults \[[@B19]-[@B22]\] and 27% in children \[[@B23]\]. Accordingly, considering the clinical importance of primary *H. pylori* resistance to clarithromycin, its prevalence should be considered before choosing eradication regimens \[[@B24]\].

Determination of *H. pylory in vitro* susceptibility to antibiotics can be performed by standard techniques such as the agar diffusion, agar dilution and broth microdilution methods and the E-test. However, because of the slow growth and the particular requirements of *H.pylori* culture, this approach is not reliable for use in most routine clinical laboratories, principally in developing countries. Hence, molecular tests targeting *H. pylori* resistance associated gene mutations directly from gastric biopsy specimens have the potential for use in large scale studies \[[@B25]-[@B29]\].

The molecular mechanism involved in clarithromycin resistance consists of mutations in the sequence of the *H. pylori* domain V of the 23S rRNA fraction which is involved in the peptiltransferase ribosome binding site preventing the ligation of the macrolide to the rRNA \[[@B30]\]. The major characterized point mutations are A to G at positions 2142 and 2143, A to C at 2142 \[[@B31]-[@B33]\], A to T at 2144 \[[@B34]\], T to C at 2717 \[[@B35]\] and C to A at 2694 \[[@B36]\]. The A2142G and A2143G mutations are predominant in clinical isolates worldwide including in Brazil \[[@B21],[@B37]-[@B40]\]. Thus, in order to perform a large scale investigation of clarithromycin primary resistance directly from biopsy specimens of 1137 patients attended at the Hospital das Clínicas of Marilia, a city in the interior of São Paulo, Brazil, we developed a polymerase chain reaction associated with restriction fragment length polymorphism (PCR-RFLP) assay to detect the A2142G and A2143G nucleotide substitutions at domain V of the *H. pylori* 23S rDNA.

Methods
=======

Patients
--------

1137 adult patients resident in Marilia city, São Paulo State of Brazil, aged 19 to 91 years, who had consecutively undergone esophagogastroduodenoscopy (EGD) for upper abdominal pain or dyspeptic symptoms from February 2003 through December 2006 at the gastroenterology outpatient clinic of the Hospital das Clínicas of Marília Medical School, were enrolled in this study.

Endoscopy and biopsies
----------------------

The EGD was accomplished by fibroendoscope (GIF-XP20, GIF-XQ20) or video-endoscope (GIF-100) both from Olympus, Shinjuku-ku, Tokyo, Japan. Gastric or duodenal ulcer diagnostic was defined by endoscopy and two fragments of the antrum were collected to perform the rapid urease and histopathological tests. The biopsy used for the rapid urease test was further submitted to DNA extraction. The protocol used is in agreement with the Helsinki Declaration and was approved by the Ethical Committee in Human Research from Marilia Medical School, under reference number 388/01. In the Ethical Committee approved research protocol a written informed consent from each patient included in this study was waived as all gastric biopsy samples analyzed were the same biopsies used routinely for urease rapid test as part of the gastroenterology outpatient service of the Hospital das Clinicas of Marilia Medical School and thus, no specific patient intervention was necessary for the enrollment in this proposed study. Accordingly, waiver of the written informed consent did not adversely affected the rights and welfare of the subjects included in this research, and also the confidentiality of the patients identity was guaranteed.

Histology
---------

One antral specimen was fixed in formol solution at 10% and embedded in paraffin. Sections were Giemsa stained for *H. pylori* evaluation and were stained with hematoxilin and eosin for assessment of histopathologic alterations \[[@B41]\].

Polymerase chain reaction, restriction and sequencing analysis
--------------------------------------------------------------

The same biopsy used for the rapid urease test was submitted to DNA extraction with the employment of the GFx DNA extraction kit purchased from Amersham/Pharmacia Biotech, following the manufacturer's instructions. DNA was quantified in agarose gel electrophoresis using the Invitrogen, Grand Island, New York, USA, low mass ladder and 50-100ug of total DNA were used in the PCR reactions with the oligonucleotides: Hp23Sr6 sense (5′ CACACAGGTAGATGAGATGAGTA3′) and Hp23Sr7 antisense (CACACAGAACCACCGGATCACTA3′), which amplified a fragment of 768pb corresponding to the domain V of the *H. pylori* 23S rDNA (Figure [1](#F1){ref-type="fig"}). To overcome the problems of extensive genetic polymorphism for precise PCR detection of *H.pylori*, the oligonucleotide construction was performed after a comparative analysis of the 23S rDNA from *H.pylori* and related organisms available at Genebank on MegAlign Lasergene software. PCR condition was 94°C 5′ followed by 40 cycles of 94°C 30″/60°C 30″/72°C 30″ and one cycle at 72°C 7′, with a total volume of 25 μl containing 1× PCR buffer, 200 μM dNTPs, 2,0 mM MgCl~2~, 1 μM of each oligonucleotide, 1,25 U Taq DNA Polimerase Platinum Brazil (Invitrogen). In all PCR reactions a negative and a positive control were used corresponding to, respectively, sterile water and *H. pylori* PCR positive gastric biopsies. The amplified fragments were digested with M*boII* and B*saI* (New England Biolabs). These enzymes distinguish mutations in the *H. pylori* domain V of the 23S rDNA at the positions 2142 and 2143, respectively. In the presence of A2142G mutation the resulting restriction DNA fragments are of 418 bp and 350 bp and in the presence of A2143G mutation the resulting fragments are of 108, 310 e 350 bp. As a control of M*boII* digestion we used a PCR amplified DNA fragment of 601 bp corresponding to the *Leishmania major* chitinase gene that contains a restriction site for M*boII*. A conserved B*saI* restriction site at the 768 bp PCR amplicon is the positive control for digestion with this enzyme producing DNA fragments of 108 and 660 bp in the absence of A2143G mutation. The products of PCR reactions and restriction analysis were resolved in 1,5% agarose gels, stained with ethidium bromide and photographed under UV light. 23S rDNA 768 bp PCR amplicons from four gastric biopsies (two positive and two negative for *H. pylori* histologic test) with clarithromycin sensitive M*boII* and B*saI* restriction pattern, and from ten gastric biopsies with clarytromycin resistant M*boII* (three samples) and B*saI* (seven samples) restriction patterns were submitted to sequencing with DyeTM Terminator v3.0 cycle Sequencing Ready Reaction kit and an ABI-3100 machine purchased from Applied Biosystem, according to the manufacturer's instructions. Nucleotide sequence determination was performed in duplicate and comparative analysis was carried out by basic nucleotide BLAST alignment \[[@B42]\].

![**Molecular diagnosis of*Helicobacter pylori*by PCR and RLFP detection of the domain V of the 23S rRNA mutations A2142G and A2143G responsible for clarithromycin resistance. A.** Representation of the *H. pylori* 23S coding gene (Genbank:HPU27270), position of the primers used for PCR and of the A2142 and A2143 from fraction V of the 23S rDNA, size of the fragments obtained with restriction enzymes BsaI and M*boII* in PCR fragments containing the mutations A2142G and A2143G, and internal B*saI* restriction site of the 768 bp amplicon, are indicated. **B, C** and **D.** Agarose gel stained with ethidium bromide containing a PCR diagnostic analysis, restriction analysis of the 768pb amplicon with M*boII* and B*saI*, respectively. 1--10 correspond to different human biopsy specimens; C-, negative control of PCR, M-100 bp ladder purchased from Invitrogen. Sizes of the DNA fragments are indicated on the left or right of each gel figure.](1471-230X-13-164-1){#F1}

Statistical analysis
--------------------

*H. pylori* diagnostic tests were evaluated by calculating sensitivity, specificity and accuracy employing histology as the gold standard.

Results and discussion
======================

This is the first Brazilian large scale study on *H. pylori* diagnosis and clarithromycin resistance directly from biopsy specimens of 1137 consecutive patients submitted to upper gastroscopy, over a four year period, in a city in the interior of São Paulo, Brazil.

Gastric disease outcome of all patients enrolled in this study attended at the gastroenterology outpatient clinic of Hospital das Clínicas of Marília was investigated by endoscopy and histopathology. Endoscopic finds of peptic or duodenal ulcer disease (PUD) was present in 123 patients. Different degrees of chronic gastritis (CG) were observed by histopathology in 706 patients and normal gastric mucosa, associated or not to gastroesophageal reflux disease (GERD) was found in 290 patients. Eighteen patients were diagnosed as having adenocarcinoma (15) and MALT lymphoma (3) and were excluded from the study. Epidemiological analysis, clinical outcome and *H. pylori* prevalence of these samples were recently published \[[@B43]\].

Detection of *H. pylori* was performed directly from biopsy specimens by three different tests: histology, a household rapid urease test and PCR with the primers Hp23Sr6/r7 which amplify a 768 bp bacterium fragment of the domain V of the 23S rDNA. Histology is the gold standard *H.pylori* diagnostic test employed in our clinical routine which together with histopathological analysis is used to decide for *H. pylori* eradication therapy. The household rapid urease test showed a very low positive predictive value for *H. pylori* associated gastric diseases and a high discrepancy when compared to histology; consequently these data were excluded from the study (data not shown). The 23S rDNA PCR method detected *H. pylori* in 488 gastric biopsies specimens where histology was positive for 451 biopsies samples. Comparative analysis of the PCR assay performed with the Hp23Sr6/r7 with histology showed sensitivity, specificity and accuracy of 77,6%, 79,3% and 78,6%, respectively (Table [1](#T1){ref-type="table"}). As both tests were performed on a single and different biopsy and *H. pylori* infection presents a focal characteristic of infection \[[@B44],[@B45]\], accuracy of 78,6% is acceptable for a trustworthy diagnostic test. It can be demonstrated by consistence of the *H.pylori* detection by PCR and histology employed in CG (53,1% and 52,7%, respectively) and PUD (61,2% and 62,6%, respectively) patients (Table [1](#T1){ref-type="table"}). PCR detected *H.pylori* in 12,75% in patients with normal gastric mucosa while histology was positive for only 0,8% of the samples. These results can be explained by the more sensitive characteristic of the acid nucleic based method. In order to improve the diagnosis of *H.pylori* some authors suggest the analysis of multiple biopsies \[[@B44]\]. In order to confirm the specificity of the PCR fragments obtained, amplicons from two samples with histologic test for *H. pylori* positive and two samples with histologic test for *H. pylori* negative were sequenced. BLASTN analysis of all four biopsy amplified PCR fragments with the 23S rDNA *H. pylori* specific primers \[Genbank:KF680642, Genbank:KF680643, Genbank:KF680644 and Genbank:KF680645\] revealed identity of 100% with the 23S rDNA referent to different strains of *H. pylori*. Accordingly, the developed PCR assay is rapid and accurate and can be used as a practical method for the detection of *H.pylori* infection.

###### 

**Clinical outcome and comparison of*H. pylori*diagnostic methods**

             **   PUD (n = 123)**        **   CG (n = 706)**         **   N (n = 290)**                         
  ---------- ---------------------- ---- --------------------- ----- -------------------- ----- --- ----- ----- ------
  **PCR+**   63                     13   76                    286   89                   375   1   36    37    488
  **PCR-**   14                     33   47                    86    245                  331   1   252   253   631
  **T**      77                     46   123                   372   334                  706   2   288   290   1119

*CG* chronic gastritis, *PUD* peptic ulcer disease, *N* normal gastric mucosa associated or not to gastroesophageal reflux disease (GERD), *PCR* polymerase chain reaction, *His* histology.

Antibiotic treatment of gastric diseases is recommended when *H. pylori* diagnosis is positive and the bacterium classic eradication therapy composed of clarithromycin, amoxicillin and a pump proton inhibitor is prescribed. The chosen therapy present a high failure of *H.pylori* eradication rate in areas where resistance to clarithromycin is higher than 15%, probably in response to the widespread use of this antibiotic for respiratory tract infection, especially in children \[[@B9]\]. Global primary resistance of *H. pylori* to clarithromycin ranges from 1 to 29% \[[@B46]\]. In Brazil, several studies reported a clarithromycin resistance prevalence of 7-16% in adults \[[@B19],[@B20],[@B22],[@B47]\] and 27% in children \[[@B23]\]. Thus, in order to improve the empirical choice of *H.pylori* associated disease therapy, we investigated the regional rate of *H.pylori* clarithromycin resistance through detection of the major related point mutations, A2142G and A2143G at domain V of the *H. pylori* 23S rDNA.

Thus, all 488 *H.pylori* PCR positive samples were analyzed by RFLP of the 768 bp PCR fragment obtained with primers Hp23Sr6/7 with the restriction enzymes M*boII* and B*saI*, with detect mutations A2142G and A2143G at domain V of the *H. pylori* 23S rDNA, respectively (Figure [1](#F1){ref-type="fig"}). Only 12 samples (2,46%) showed the mutated restriction pattern, three (25%) harboring A2142G mutation, seven (58,3%) A2143G and one sample (8,7%) showed both rDNA point mutations in the PCR 23S rDNA 768 bp fragment. One sample showed partial digestion with the enzyme M*boII* (Figure [1](#F1){ref-type="fig"}). The point mutations A2142G and A2143G of the amplicons obtained from three \[Genbank:KF680646, Genbank:KF680647 and Genbank:KF680647\] and seven \[Genbank:680649, Genbank:680650, Genbank:680651, Genbank:680652, Genbank:680653, Genbank:680654 and Genbank:680655\] different biopsies samples, respectively, were confirmed by sequencing. There was no association of clarithromycin *H.pylori* resistance point mutations with patients' age or gender (data not shown).

The prevalence of *H. pylori* clarithromycin resistance found in our region was similar to that found in developed countries such as Italy and Germany \[[@B7]\] and in the South American developing country Paraguay \[[@B48]\]. These results confirm the high regional variability of *H.pylori* antibiotic resistance and spite of increasing clarithromycin resistance worldwide, in Marilia, a low resistance rate was maintained over the period of four years. Moreover, PCR/RFLP was a rapid and accurate method for the detection of clarithromycin resistance through a gene mutation directly in gastric biospsy samples and can be used together with histology to decide for prescription of clarithromycin containing regimen therapy.

*H. pylori* 23S rRNA domain V A2142G and A2143G point mutations are the major mutations found in *H. pylori* clinical isolates resistant to clarithromycin. We found a higher prevalence of A2143G compared to A2142G mutation in our samples which is in agreement with the majority of Brazilian studies including the States of Minas Gerais, São Paulo and Recife \[[@B20],[@B34],[@B36]\]. A2143G but not A2142G point mutation shows a synergistic effect of clarithromycin and amoxicillin, which have been used together in the first-line *H. pylori* regimen \[[@B49]\], reinforcing the necessity to investigate this clarithromycin 23S rDNA point mutation before treatment. One sample harbored both A2142G and A2143G mutations at domain V of the *H. pylori* 23S rDNA that was also found in three *H.pylori* isolates obtained from patients of the Brazilian State of Minas Gerais \[[@B20]\]. These results together with the occurrence of partial digestion of a 768 bp 23S rDNA PCR fragment (Figure [1](#F1){ref-type="fig"}) can be indicative of stomach colonization of multiple strains of *H.pylori*\[[@B50]\].

In Minas Gerais, Brazil, clarithromycin resistance has increased from 4,48% in 1996 to 19,05% in 2000 \[[@B20]\], probably due to the use of macrolides in the treatment of other infectious diseases. We did not find any significant difference in samples resistant to clarithromycin according to the period of the study (data not shown). These data indicate that in our region the prescription and utilization of macrolides is not performed on a high scale. More studies are necessary to confirm this hypothesis.

Clarithromycin resistance reduces the clinical efficacy of clarithromycin-based triple therapy. However, as prevalence of primary resistance of *H.pylori* to clarithromycin due to the rDNA 23S A2142G and A2143G nucleotide substitutions remains low in Marilia, the standard clarithromycin containing triple therapy is still valid as the most effective empirical first-line eradication therapy for *H. pylori* infection.

Conclusions
===========

The developed PCR assay targeted to the 23S rDNA gene of *H. pylori* is rapid and accurate and can be used as a practical method for the detection of *H.pylori* infection directly on gastric biopsy specimens. Furthermore, the *H. pylori* 23S rDNA PCR fragment obtained can be used to detect point mutations from 1728 to 2495 bp of the *H. pylori* 23S rDNA domain V associated to clarithromycin resistance. Prevalence of primary resistance of *H.pylori* to clarithromycin due to 23S rDNA A2142G and A2143G nucleotide substitutions remains low in Marilia, thus the standard clarithromycin containing triple therapy is still valid as the most effective empirical first-line eradication therapy for *H. pylori* infection.
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